Prevention of Mushroom Broomstick Diseases
Flammulina witches' broom is a physiological disease. When the infected bacterial bag or bottle enters the fruiting body formation stage, only the long stipe does not form a cap. The specific performance is as follows: When the stipe is extended to a certain length, the top produces branches, and then the branches produce small branches, the longer the smaller branches, the more subtle and drooping; the cap of the stump is stagnant in the young form when the primordium is developed, and the diameter is only It is 1 to 2 mm; the whole mushroom body is whisker-shaped and fruit body growth is severely inhibited with almost no yield.
Causes of Mushroom witches'-broom disease are mainly caused by poor ventilation of the mushroom farm, high carbon dioxide concentration, high humidity, and lack of weak light stimulation, inhibiting the growth of the cap, and thus the disease is more common in the air circulation holes, tunnels Planting places.
To prevent Mushroom witches' broom disease, it is necessary to have good ventilation conditions for the mushrooming places. After the bottle-planting velutine mushroom is formed in the fruit body primordium, it is necessary to carry out 3 to 5 days of mushroom formation and culture before bagging the oyster mushroom. After bagging, the bag should be moved up and down 1 or 2 times per day. The bag-planted golden mushroom needs to be ventilated in the early stage of fruit body growth, and the cover can be opened to promote the differentiation of the cap and stipe thickening. After the normal development of the cap, the management method of the mushroom is implemented. When the growth of the mushroom bud was found to be abnormal, and the tip of the stipe was forked and drooped, the mushroom was promptly removed, and the environmental conditions conducive to the formation of the fruit body were created and the normal growth could still be achieved.
We supply high purity Lapatinib API and its intermediates, which is for the treatment of advanced or metastatic breast cancer. They are Lapatinib base (231277-92-2); Lapatinib Ditosylate MonohydrateI (388082-78-8); 3-Chloro-4-(3-fluoro-benzyloxy)-phenylamine (202197-26-0); N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-iodoquinazolin-4-amine (231278-20-9).
If you have any questions, please contact with us directly!
Cas 202197-26-0,Lapatinib Intermediates,Jp Lapatinib
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com